Search our website

Press Releases

VBI Vaccines Appoints Linda Bain to Board of Directors
July 7th, 2021
VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine
July 1st, 2021
VBI Vaccines Announces Initial Positive Phase 1 Data for its eVLP Vaccine Candidate Against COVID-19
June 29th, 2021
Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
June 23rd, 2021
VBI Vaccines to Present at Upcoming Scientific Conferences
June 17th, 2021
VBI Vaccines Announces Results of Annual General Meeting
June 9th, 2021
VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at EASL 2021
June 9th, 2021
VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM
June 8th, 2021
VBI Vaccines to Participate in Upcoming Investor Conferences
June 1st, 2021
VBI Vaccines Announces $12 Million Second Tranche of Debt Financing with K2 HealthVentures
May 21st, 2021
VBI Vaccines to Present Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting
May 20th, 2021
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious Diseases
May 12th, 2021
VBI Vaccines Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 10th, 2021
VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021
May 3rd, 2021
VBI Vaccines Announces Publication of Preclinical and Challenge Study Data of its eVLP Vaccine Candidate Against COVID-19 (VBI-2902)
April 28th, 2021
VBI Vaccines to Participate in National Securities Corporation’s Biotech Investor Summit
April 27th, 2021
VBI Vaccines Announces Presentation at the 2021 Annual Conference on Vaccinology Research
April 26th, 2021
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
April 21st, 2021
VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate
April 12th, 2021
VBI Vaccines to Present at Oppenheimer 31st Annual Healthcare Conference
March 15th, 2021

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI

Sign Up NowArrow
Go top